Dave Fornell, DAIC Editor

Dave Fornell, Editor DAIC

Blog | Dave Fornell, DAIC Editor | November 15, 2013

Micro Pacemaker May Help Revolutionize Electrophysiology

By Dave Fornell, DAIC editor

It was just a couple years ago in a session at the American College of Cardiology on possible science-fiction-type cardiac technologies of the future that I first saw a slide of experimental, tiny catheter-delivered pacemakers that may some day revolutionize the field of electrophysiology (EP). In October, one of those science fiction devices, the Nanostim pacemaker, was granted market clearance in Europe and it was announced the vendor is in discussions to enter U.S clinical trials. I’m sure it is the first of many new miniaturized EP devices to come that will significantly change how patients with arrhythmias are treated.

When attending cardiology conferences, I am always on the lookout for “sexy” new technologies.  This admittedly is sometimes difficult to find among a sea of academic sessions and vendors on the expo floor who are always attempting to peddle what they perceive to be the greatest invention since sliced bread. However, the Nanostim is definitely one of those rare sexy technologies that we usually only find in the fictional worlds of futuristic Hollywood movies.

The tiny device, about the size of the head of a pen, can be delivered via a delivery catheter through the venous system and placed directly into the myocardium of the right ventricle.  The system eliminates the need for surgery to create a pocket under the skin for the device, or to install traditional leads.  This greatly simplifies the procedure and reduces the risk of potential complications such as infection, or the need to remove old leads years in the future. The simplified procedure cuts implant time down to an average of 28 minutes. 

One of the biggest issues facing EP is device battery life, as patients live longer or have devices implanted at a younger age. Even with miniaturization, Nanostim’s battery is expected to have an average lifespan of more than nine years at 100 percent pacing, or more than 13 years at 50 percent. 

Speaking of battery replacement, another advantage of the system is that it was designed to be fully retrievable so it can be readily repositioned during the implant procedure, or later retrieved for normal battery replacement.

What I find more intriguing are the possibilities this type of device may have on simplifying the practice of EP, possibly offering a way to more efficiently treat larger numbers of patients at a lower cost.  The delivery of this type of device might also open the possibility of implants by new operators, such as interventional cardiologists.  This might have the biggest impact in rural areas of the United States or in developing countries, where EP specialists are often rare.  

For more on the Nanostim and other EP technology developments in 2013 click here, or watch a video showing the Nanostim implantation procedure.

Related Content

Lenox Hill Hospital Opens New Heart Rhythm Center
News | EP Lab | August 27, 2019
Lenox Hill Hospital (New York, N.Y.) has established a brand new Heart Rhythm Center dedicated to the treatment of...
Damaged Hearts Rewired With Nanotube Fibers

Researchers at Texas Heart Institute and Rice University have confirmed that flexible, conductive fibers made of carbon nanotubes can bridge damaged tissue to deliver electrical signals and keep hearts beating despite congestive heart failure or dilated cardiomyopathy or after a heart attack. Image courtesy of Texas Heart Institute.

News | EP Lab | August 15, 2019
Thin, flexible fibers made of carbon nanotubes have now proven able to bridge damaged heart tissues and deliver the...
Cardiac Device Complications Vary Widely Among Hospitals
News | EP Lab | July 31, 2019
The chances of patients experiencing complications after having a cardiac device implanted vary according to where they...
A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] The new scoring system was presented as a follow up to that study during a late-breaking session at Heart Rhythm 2019, the Heart Rhythm Society's 40th Annual Scientific Sessions.

Figure 1: The PADIT infection risk score ranging from 0 to 14 points classified patients into three risk groups, low (0-4), intermediate (5-6) and high (≥7). The risk groups had rates of hospitalization for infection of 0.51%, 1.42% and 3.41%, respectively 

News | EP Lab | May 15, 2019
May 15, 2019 — A new infection risk scoring system has been developed based on data from the large PADIT Trial.[1] Th
Studies Find Race and Gender Disparities in Implantable Heart Devices
News | EP Lab | May 15, 2019
May 15, 2019 - Three new studies show that patients who are medically indicated for implantable heart devices, includ
Heart Rhythm 2019 study shows travelers with common cardiac devices can pass through without restrictions or precautions. HRS 2019, #HRS #HRS19

A new study shows travelers with common cardiac devices can pass through airport body scanners without restrictions or precautions.

News | EP Lab | May 14, 2019
May 14, 2019 – Results from new research show that passengers with cardiac implantable electronic devices (CIEDs), su
News | EP Lab | May 13, 2019
May 13, 2019 – Results from a new survey are the first to report a large discrepancy in patient’s knowledge of their
Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Concerto CRT-D and Virtuoso ICD implantable cardiac devices are among several Medtronic electrophysiology devices included in a safety alert because of their lack of cybersecurity measures to avoid hacking, according to the FDA.

Feature | EP Lab | March 22, 2019
March 22, 2019 — The U.S.
Overlay Init